Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II. Clinical Trial

Status Recruiting

Clinical Trial Summary

Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP).

Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Retinopathy of Prematurity
• Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.

• NCT number: NCT01707745
• Study type: Interventional
• Source: Dubai Health Authority
• Contact: Sivakami A Pai, MS, DNB, Phd
• Phone: 00971504148256
• Status: Recruiting
• Phase: N/A
• Start date: January 2010
• Completion date: December 2012